GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera Inc (NAS:BFRI) » Definitions » Effective Interest Rate on Debt %

Biofrontera (Biofrontera) Effective Interest Rate on Debt % : 125.41% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Biofrontera Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Biofrontera's annualized positive value of Interest Expense for the quarter that ended in Mar. 2024 was $5.68 Mil. Biofrontera's average total debt for the quarter that ended in Mar. 2024 was $4.53 Mil. Therefore, Biofrontera's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 was 125.41%.


Biofrontera Effective Interest Rate on Debt % Historical Data

The historical data trend for Biofrontera's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofrontera Effective Interest Rate on Debt % Chart

Biofrontera Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
5.65 7.58 - 27.49 17.79

Biofrontera Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.49 28.44 24.76 22.70 125.41

Competitive Comparison of Biofrontera's Effective Interest Rate on Debt %

For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biofrontera's Effective Interest Rate on Debt % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofrontera's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Biofrontera's Effective Interest Rate on Debt % falls into.



Biofrontera Effective Interest Rate on Debt % Calculation

Biofrontera's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  -0.6/( (1.346+5.399)/ 2 )
=-1  *  -0.6/3.3725
=17.79 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.848 + 0.498
=1.346

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.804 + 4.595
=5.399

Biofrontera's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2023 )+Total Debt  (Q: Mar. 2024 ))/ count )
=-1  *  -5.684/( (5.399+3.666)/ 2 )
=-1  *  -5.684/4.5325
=125.41 %

where

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.804 + 4.595
=5.399

Total Debt  (Q: Mar. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.621 + 3.045
=3.666

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Biofrontera  (NAS:BFRI) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Biofrontera Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Biofrontera's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biofrontera (Biofrontera) Business Description

Industry
Traded in Other Exchanges
N/A
Address
120 Presidential Way, Suite 330, Woburn, MA, USA, 01801
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
Executives
Heikki Lanckriet director C/O BIOFRONTERA INC., 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Eugene Frederick Leffler officer: Chief Financial Officer 84 BAY DRIVE, SUDBURY MA 01776
Kevin Daniel Weber director 119 BUCHANAN COURT, CELINA TX 75009
Borer John J Iii director 1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020
Beth J. Hoffman director 5895 BLAZING STAR LANE, SAN DIEGO CA 92130
Loretta M. Wedge director 21260 WACISSA DRIVE, VENICE FL 34293
Ag Biofrontera 10 percent owner HEMMELRATHER WEG 201, LEVERKUSEN 2M D-51377
Erica F. Gates officer: Controller C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Erica L. Monaco director, officer: Chief Financial Officer/COO C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Hermann Luebbert director, officer: Chief Executive Officer C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801